Qube Research & Technologies LTD Mirati Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$41.99 - $62.38 $1.02 Million - $1.52 Million	24,374 New	24,374 $1.43 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $2.38 Million - $3.47 Million	40,038 Added 239.69%	56,742 $3.96 Million
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $861,950 - $1.95 Million	-22,011 Reduced 56.85%	16,704 $1.12 Million
Q1 2022 May 09, 2022	BUY	$75.82 - $150.97 $2.94 Million - $5.84 Million	38,715 New	38,715 $3.18 Million
Q3 2021 Nov 12, 2021	SELL	$132.13 - $177.45 $2.9 Million - $3.9 Million	-21,964 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$144.0 - $179.73 $3.16 Million - $3.95 Million	21,964 New	21,964 $3.55 Million
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $566,202 - $839,503	-3,494 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$113.26 - $167.27 $395,730 - $584,441	3,494 New	3,494 $580,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.